

Daniel O Connor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5699403/daniel-oconnor-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-------------------------|-----------------|-----------------|
| 41 papers | 4,773 citations | 14 h-index | 48 g-index |
| 48 ext. papers | 7,324 ext. citations | 13.9 avg, IF | 4.35 L-index |

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 41 | A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.. <i>Cell</i> , 2022 , 185, 916-938, e58 | 56.2 | 17 |
| 40 | Divergent trajectories of antiviral memory after SARS-CoV-2 infection.. <i>Nature Communications</i> , 2022 , 13, 1251 | 17.4 | 1 |
| 39 | Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022 , 77, 102210 | 7.8 | 2 |
| 38 | Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen. <i>BMC Genomics</i> , 2021 , 22, 777 | 4.5 | 1 |
| 37 | Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2021 , 396, 1979-1993 | 40 | 646 |
| 36 | RNA2HLA: HLA-based quality control of RNA-seq datasets. <i>Briefings in Bioinformatics</i> , 2021 , 22, | 13.4 | 1 |
| 35 | Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease. <i>European Journal of Human Genetics</i> , 2021 , 29, 1734-1744 | 5.3 | 2 |
| 34 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021 , 397, 99-111 | 40 | 2110 |
| 33 | Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021 , 27, 279-288 | 50.5 | 135 |
| 32 | T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021 , 27, 270-278 | 50.5 | 225 |
| 31 | Changes in epigenetic profiles throughout early childhood and their relationship to the response to pneumococcal vaccination. <i>Clinical Epigenetics</i> , 2021 , 13, 29 | 7.7 | 0 |
| 30 | Symptom study app provides real-world data on COVID-19 vaccines. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 890-891 | 25.5 | 2 |
| 29 | Host gene signature shows promise to distinguish bacterial and viral infections. <i>The Lancet Digital Health</i> , 2021 , 3, e465-e466 | 14.4 | 0 |
| 28 | Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , 2021 , 12, 5125 | 17.4 | 3 |
| 27 | Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa143 | 1 | 1 |
| 26 | Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. <i>Molecular Systems Biology</i> , 2020 , 16, e9888 | 12.2 | 2 |
| 25 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020 , 396, 467-478 | 40 | 1274 |

| | | | |
|----|---|------|----|
| 24 | Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. <i>Journal of Infectious Diseases</i> , 2020 , 222, S666-S671 | 7 | 4 |
| 23 | Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. <i>Genes and Immunity</i> , 2020 , 21, 63-70 | 4.4 | 3 |
| 22 | Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. <i>Cell Reports</i> , 2019 , 27, 3241-3253.e4 | 10.6 | 16 |
| 21 | Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: Mycobacterial Growth Inhibition Predicts Outcome of Mycobacterial Infection. <i>Frontiers in Immunology</i> , 2019 , 10, 2983 | 8.4 | 13 |
| 20 | The effect of H1N1 vaccination on serum miRNA expression in children: A tale of caution for microRNA microarray studies. <i>PLoS ONE</i> , 2019 , 14, e0221143 | 3.7 | 2 |
| 19 | Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component. <i>Scientific Reports</i> , 2019 , 9, 13797 | 4.9 | 7 |
| 18 | A naturally protective epitope of limited variability as an influenza vaccine target. <i>Nature Communications</i> , 2018 , 9, 3859 | 17.4 | 23 |
| 17 | High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. <i>Genome Medicine</i> , 2017 , 9, 11 | 14.4 | 10 |
| 16 | The Clinical Application of MicroRNAs in Infectious Disease. <i>Frontiers in Immunology</i> , 2017 , 8, 1182 | 8.4 | 97 |
| 15 | Non-specific immunological effects of selected routine childhood immunisations: systematic review. <i>BMJ, The</i> , 2016 , 355, i5225 | 5.9 | 45 |
| 14 | Gene expression profiles are different in venous and capillary blood: Implications for vaccine studies. <i>Vaccine</i> , 2016 , 34, 5306-5313 | 4.1 | 2 |
| 13 | Searching for the human genetic factors standing in the way of universally effective vaccines. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015 , 370, | 5.8 | 29 |
| 12 | The use of systems biology and immunological big data to guide vaccine development. <i>Genome Medicine</i> , 2015 , 7, 114 | 14.4 | 9 |
| 11 | The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses. <i>Journal of Infectious Diseases</i> , 2014 , 209, 1635-41 | 7 | 14 |
| 10 | Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine. <i>Vaccine</i> , 2014 , 32, 3424-30 | 4.1 | 2 |
| 9 | The B-cell response to a primary and booster course of MenACWY-CRM vaccine administered at 2, 4 and 12 months of age. <i>Vaccine</i> , 2013 , 31, 2441-8 | 4.1 | 15 |
| 8 | Genetic material should be routinely collected in clinical vaccine trials--high consent rates can be achieved across all age groups. <i>Vaccine</i> , 2013 , 31, 2744-8 | 4.1 | 1 |
| 7 | Characterizing vaccine responses using host genomic and transcriptomic analysis. <i>Clinical Infectious Diseases</i> , 2013 , 57, 860-9 | 11.6 | 23 |

| | | | |
|---|--|-----|----|
| 6 | Seroprevalence and placental transmission of maternal antibodies specific for <i>Neisseria meningitidis</i> Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom. <i>Pediatric Infectious Disease Journal</i> , 2013 , 32, 768-76 | 3-4 | 14 |
| 5 | Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine. <i>Vaccine Journal</i> , 2012 , 19, 295-303 | | 13 |
| 4 | Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leukocyte antigen locus | | 1 |
| 3 | Immunogenicity1-8 | | |
| 2 | A blood atlas of COVID-19 defines hallmarks of disease severity and specificity | | 4 |
| 1 | Divergent trajectories of antiviral memory after SARS-Cov-2 infection | | 4 |